Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Small Cell Lung Carcinoma 30Burkitt Lymphoma 12Lung Neoplasms 11Leukemia, Myeloid, Acute 11Recurrence 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Carcinoma, Non-Small-Cell Lung 7Neuroblastoma 4Lymphoma, B-Cell 4Leukemia 4Wilms Tumor 3Sarcoma, Ewing 3Plasmablastic Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Immunoblastic Lymphadenopathy 3Ganglioneuroblastoma 3Teratoma 2Sarcoma 2

Interventions

Cyclophosphamide 3Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2tazemetostat 1pembrolizumab 1fludarabine 1etoposide phosphate 1duvelisib 1Prednisolone 1Melphalan 1Cytarabine 1Carmustine 1Azacitidine 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enteropathy-Associated T-Cell Lymphoma × Etoposide × 90 days × Clear all
NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡